Perrigo cough/cold sales grow 27% in 2nd quarter, contributing to 11% OTC sales gain.
This article was originally published in The Tan Sheet
Executive Summary
PERRIGO COUGH/COLD SALES RISE 27% IN THE SECOND QUARTER ended Dec. 31 because of a "much stronger" cough and cold season than last year, the company said Feb. 6. In the first half of fiscal 1996, cough/cold product sales were ahead 20%. In contrast, however, a "moderate" flu season as well as a "soft and competitive" market caused analgesic sales to drop "slightly" in the quarter, the Allegan, Mich.-based store-brand manufacturer noted